For the list, Medicare’s top 20 costliest drugs in 2015 were ranked according to their cost above the program’s catastrophic coverage threshold. Medicare’s catastrophic coverage threshold is $4,850 in 2016. After a Medicare beneficiary’s out-of-pocket spending reaches this amount, new payment levels for future healthcare costs kick in. The beneficiary pays only 5 percent of costs, the insurer pays 15 percent and taxpayers cover 80 percent.
- Harvoni (hepatitis C treatment): $6.3 billion
- Revlimid (cancer): $1.7 billion
- Sovaldi (hepatitis C): $1.2 billion
- Copaxone (multiple sclerosis): $1.1 billion
- Gleevec (cancer): $1 billion
- Humira Pen (rheumatoid arthritis): $886 million
- Tecfidera (multiple sclerosis): $724 million
- Renvela (kidney disease): $675 million
- Xtandi (prostate cancer): $633 million
- Lantus Solostar (diabetes): $633 million
- Zytiga (prostate cancer): $623 million
- Enbrel Sureclick (rheumatoid arthritis): $586 million
- Abilify (mental illness): $555 million
- Sensipar (kidney disease): $533 million
- Truvada (HIV) $525 million
- Aripiprazole (mental illness): $504 million
- Lantus (diabetes): $484 million
- Imbruvica (cancer): $473 million
- H.P. Acthar (multiple sclerosis): $467 million
- Lyrica (seizures): $461 million
More articles on finance issues:
Hospital cost, quality ranking site aims to help employers manage costs
Supplemental nursing home Medicaid funding on the chopping block in Texas
Athenahealth will reimburse clients for MIPS-related payment cuts in new guarantee
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
